Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
Earnings Data
Report Date
May 28, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.65Last Year’s EPS
-1.05Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 19, 2025
|% Change Since: -15.57%
|Next Earnings Date:May 28, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant clinical and commercial progress, particularly with EscharEx and NexoBrid, along with strategic collaborations and a strong financial backing. However, the increased operating and net losses, along with a decline in gross margin, suggest financial challenges. The positive advancements in products and strategic partnerships indicate a promising outlook despite these financial hurdles.Company Guidance
During the MediWound earnings call for the fourth quarter and full year 2024, management provided comprehensive guidance and future projections. EscharEx, their next-generation enzymatic debridement therapy, demonstrated superiority over SANTYL in clinical endpoints, with a peak sales potential estimated at $725 million. The ongoing VALUE Global Phase 3 trial for venous leg ulcers involves 216 patients across 40 sites, with interim results expected in mid-2026 and completion by year-end 2026. The company anticipates a 2025 revenue of $24 million for NexoBrid, up from $20.2 million in 2024, and highlighted an FDA approval for pediatric use. The newly constructed GMP manufacturing facility is set for full capacity by late 2025, with regulatory approvals projected for 2026. Financially, MediWound reported a 2024 total revenue of $20.2 million, a gross margin of 13%, and an operating loss of $19.4 million. The company ended the year with $43.6 million in cash and a robust cash runway of approximately $44 million, supporting its ambitious clinical and commercial objectives.Strong Clinical Progress with EscharEx
Reported compelling results from a head-to-head analysis against SANTYL, demonstrating EscharEx’s superiority in key clinical endpoints like complete debridement and wound closure. Market research estimates peak sales potential at approximately $725 million.
Expanded Commercial Reach for NexoBrid
NexoBrid generated $20.2 million in revenue with a projected increase to $24 million in 2025. Expanded reach in Europe, Japan, and the US, with a 42% increase in US hospital orders in Q4 2024.
Strategic Collaborations and Funding
Secured €16.5 million from the European Innovation Council for EscharEx development and entered strategic research collaborations with key industry partners like Solventum, Mölnlycke, and MIMEDX.
Completed State-of-the-Art GMP Manufacturing Facility
Successfully completed construction of a new manufacturing facility, expected to reach full operational capacity by late 2025, with regulatory approval anticipated in 2026.
$25 Million PIPE Financing Round
Strengthened balance sheet with a $25 million PIPE financing round led by Mölnlycke, reflecting industry confidence.
---
MDWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 19, 2025 | $19.27 | $18.28 | -5.14% |
| Nov 26, 2024 | $17.33 | $16.90 | -2.48% |
| Aug 14, 2024 | $18.21 | $17.47 | -4.06% |
| May 29, 2024 | $17.79 | $16.01 | -10.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mediwound (MDWD) report earnings?
Mediwound (MDWD) is schdueled to report earning on May 28, 2025, TBA Not Confirmed.
What is Mediwound (MDWD) earnings time?
Mediwound (MDWD) earnings time is at May 28, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDWD EPS forecast?
MDWD EPS forecast for the fiscal quarter 2025 (Q1) is -0.65.
---